Letrozole May Cut Risk of Breast Cancer |
by: Darrin Kiessling
10/10/2003
Health officials recently halted a large international study after
an early review of the results suggested that the anti-estrogen drug
letrozole dramatically reduces the risk of recurrence of cancer among
of breast cancer survivors.
About 211,300 new cases of breast cancer are expected
to be diagnosed this year in the United States , two-thirds
of them in women who have gone through menopause. Most tumors will be
estrogen-receptor positive, meaning that the hormone fuels their growth...
|
|
Tesmilifene in Addition to Doxorubicin Improves Survival in Advanced Breast Cancer |
By: 411Cancer.com
02/19/2004
According to a recent article published in the Journal
of Clinical Oncology, a novel agent tesmilifene (DPPE,
BMS-217380-01) in addition to doxorubicin (Adriamycin ®) improves survival
compared to doxorubicin alone in the treatment of advanced
breast cancer.
Breast cancer is diagnosed in over 200,000 women annually in the United States alone...
|
|
Doxil ® Plus Gemzar ® Active in Metastatic Breast Cancer |
|
By: 411Cancer.com
09/23/2003
According to results recently published in the Journal
of Clinical Oncology, the chemotherapy combination of
Doxil ® plus Gemzar ® appears
active and well tolerated for the treatment of metastatic
breast cancer.
Metastatic breast cancer refers to cancer that has spread
outside the breast to several and/or distant sites in the body....
;
|
|
